Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR22846-238] to Factor IX/PTC
- Suitable for: WB, IP
- Reacts with: Human
Product nameAnti-Factor IX/PTC antibody [EPR22846-238]
See all Factor IX/PTC primary antibodies
DescriptionRabbit monoclonal [EPR22846-238] to Factor IX/PTC
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
Recombinant fragment within Human Factor IX/PTC aa 1 to the C-terminus. The exact sequence is proprietary.
Database link: P00740
- WB: Human liver and Human plasma lysates. IP: Human plasma.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab255824 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 30, 45, 66 kDa (predicted molecular weight: 52 kDa).|
FunctionFactor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.
Tissue specificitySynthesized primarily in the liver and secreted in plasma.
Involvement in diseaseDefects in F9 are the cause of recessive X-linked hemophilia B (HEMB) [MIM:306900]; also known as Christmas disease.
Note=Mutations in position 43 (Oxford-3, San Dimas) and 46 (Cambridge) prevents cleavage of the propeptide, mutation in position 93 (Alabama) probably fails to bind to cell membranes, mutation in position 191 (Chapel-Hill) or in position 226 (Nagoya OR Hilo) prevent cleavage of the activation peptide.
Defects in F9 are the cause of thrombophilia due to factor IX defect (THR-FIX) [MIM:300807]. A hemostatic disorder characterized by a tendency to thrombosis.
Sequence similaritiesBelongs to the peptidase S1 family.
Contains 2 EGF-like domains.
Contains 1 Gla (gamma-carboxy-glutamate) domain.
Contains 1 peptidase S1 domain.
DomainCalcium binds to the gamma-carboxyglutamic acid (Gla) residues and, with stronger affinity, to another site, beyond the Gla domain.
modificationsActivated by factor XIa, which excises the activation peptide.
The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.
- Information by UniProt
- Christmas Disease antibody
- Christmas factor antibody
- Coagulant factor IX antibody
All lanes : Anti-Factor IX/PTC antibody [EPR22846-238] (ab255824) at 1/1000 dilution
Lane 1 : Human liver lysate
Lane 2 : Human plasma
Lysates/proteins at 20 µg per lane.
All lanes : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
Predicted band size: 52 kDa
Observed band size: 30,45,66 kDa why is the actual band size different from the predicted?
Exposure time: Lane 1:3 minutes; Lane 2:6 seconds.
Blocking and Diluting Buffer and concentration: 5% NFDM/TBST.
Factor IX is a glycoprotein. Zymogen FIX (66 kDa), intermediate FIXα (45 kDa), and heavy chain of FIXaβ (30 kDa) are observed. The molecular weight observed is consistent with what has been described in the literature (PMID: 20110423, 2294100, 18192270).
Factor IX/PTC was immunoprecipitated from 0.35 mg Human plasma with ab255824 at 1/30 dilution (2µg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab255824 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/5000 dilution.
Lane 1: Human plasma 10µg
Lane 2: ab255824 IP in Human plasma
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab255824 in Human plasma.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 10 seconds.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab255824 has not yet been referenced specifically in any publications.